Negar Mashoori - Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran- Kaviani Breast Disease Institute (KBDI), Tehran, Iran
Sanaz Zand - Kaviani Breast Disease Institute (KBDI), Tehran, Iran
Ryan Nazemian - Department of Anesthesiology, University Hospitals, Cleveland Medical Center, USA- Institute for Transformative Molecular Medicine, Case Western Reserve University, USA
Ahmad Kaviani - Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran- Kaviani Breast Disease Institute (KBDI), Tehran, Iran

Background: Breast cancer is the most prevalent site-specific cancer and oneof the most frequent causes of cancer death in women worldwide. Neoadjuvantchemotherapy, along with surgical treatment—breast conserving surgery (BCS) ormastectomy—is an important part of treatment for locally advanced breast cancer.As BCS is preferred to mastectomy in terms of cosmetic, quality-of-life, andfunctional outcomes, it would be the preferred treatment for locally advancedbreast cancer (LABC), if its oncological safety is confirmed.Methods: In this study, we retrospectively compared the oncologic outcomesof post-neoadjuvant chemotherapy BCS with mastectomy in ۲۰۲ patients withLABC.Results: There were no significant differences between BCS and mastectomyregarding overall survival, local recurrence, contralateral breast cancer, and distantmetastasis.Conclusions: Our study showed that post-neoadjuvant chemotherapy BCS isan oncologically safe surgical treatment in LABC and that BCS can be consideredas an acceptable treatment in selected patients with LABC.

Breast cancer, neoadjuvant chemotherapy, mastectomy, breast-conserving surgery, outcome, survival